

Fulcrum Therapeutics to Present at the 18th Annual Fragile X and Related Neurodevelopmental Disorders Workshop

October 11, 2017

Cambridge, Mass., Oct. 11, 2017 – [Fulcrum Therapeutics](#), a company focused on discovering and developing small molecule therapies to unlock gene control and treat serious genetic diseases, will present at the 18th International Fragile X and Related Neurodevelopmental Disorders Workshop, held in Quebec, Canada from October 12-16, 2017.

Angela Cacace, Ph.D., Fulcrum's Vice President of Biology, will give a presentation titled "Discovery of small molecule modulators of FMR1 gene expression using iPSC-derived Fragile X neurons" at 4:45 p.m. on Saturday, October 14th in the Mastigouche Room of the Hôtel Sacacomie.

About Fulcrum Therapeutics

Fulcrum Therapeutics is a biotechnology company developing new medicines to deliver a new future to patients and their families by transforming gene regulation in disease. Fulcrum's therapies are based on modulating gene regulation via control of genetic on and off switches of disease genes. Fulcrum, headquartered in Cambridge, Mass., was launched by Third Rock Ventures in 2016 and named a "Fierce 15" company later that year. For more information, please visit www.fulcrumtx.com.

CONTACTS:

Media:
Sarah Sutton
Ten Bridge Communications
sarah@tenbridgecommunications.com
518-932-3680